CCL5 as a potential immunotherapeutic target in triple-negative breast cancer

被引:77
|
作者
Lv, Dandan [1 ]
Zhang, Yan [2 ]
Kim, Ha-Jeong [2 ]
Zhang, Lixing [1 ]
Ma, Xiaojing [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Sheng Yushou Ctr Cell Biol & Immunol, Shanghai 20040, Peoples R China
[2] Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY USA
关键词
triple negative breast cancer; CCL5; myeloid derived suppressor cell; immunotherapy; RANTES PROMOTER POLYMORPHISM; ALPHA-INDUCED SECRETION; SMOOTH-MUSCLE CELLS; GENETIC RISK-FACTOR; CHEMOKINE RANTES; MAMMARY-CARCINOMA; ELEVATED EXPRESSION; REGULATORY REGION; PROGNOSTIC-FACTOR; SUPPRESSOR-CELLS;
D O I
10.1038/cmi.2012.69
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Breast cancer (BC) is a leading cause of mortality among women in the world. To date, a number of molecules have been established as disease status indicators and therapeutic targets. The best known among them are estrogen receptor-alpha (ER-alpha), progesterone receptor (PR) and HER-2/neu. About 15%-20% BC patients do not respond effectively to therapies targeting these classes of tumor-promoting factors. Thus, additional targets are strongly and urgently sought after in therapy for human BCs negative for ER, PR and HER-2, the so-called triple-negative BC (TNBC). Recent clinical work has revealed that CC chemokine ligand 5 (CCL5) is strongly associated with the progression of BC, particularly TNBC. How CCL5 contributes to the development of TNBC is not well understood. Experimental animal studies have begun to address the mechanistic issue. In this article, we will review the clinical and laboratory work in this area that has led to our own hypothesis that targeting CCL5 in TNBCs will have favorable therapeutic outcomes with minimal adverse impact on the general physiology.
引用
收藏
页码:303 / 310
页数:8
相关论文
共 50 条
  • [31] Evolving immunotherapeutic solutions for triple-negative breast carcinoma
    Wu, Shiting
    Ge, Anqi
    Deng, Xianguang
    Liu, Lifang
    Wang, Yue
    CANCER TREATMENT REVIEWS, 2024, 130
  • [32] Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
    Stagg, John
    Allard, Bertrand
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2013, 5 (03) : 169 - 181
  • [33] Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives
    Oualla, Karima
    Kassem, Loay
    Nouiakh, Lamiae
    Amaadour, Lamiae
    Benbrahim, Zineb
    Arifi, Samia
    Mellas, Nawfel
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2020, 2020
  • [34] Evaluating immunotherapeutic outcomes in triple-negative breast cancer with a cholesterol radiotracer in mice
    Ciavattone, Nicholas G.
    Guan, Nan
    Farfel, Alex
    Stauff, Jenelle
    Desmond, Timothy
    Viglianti, Benjamin L.
    Scott, Peter J. H.
    Brooks, Allen F.
    Luker, Gary D.
    JCI INSIGHT, 2024, 9 (08)
  • [35] Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
    Corkery, B.
    Crown, J.
    Clynes, M.
    O'Donovan, N.
    ANNALS OF ONCOLOGY, 2009, 20 (05) : 862 - 867
  • [36] PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer
    Pellizzari, Sierra
    Bhat, Vasudeva
    Athwal, Harjot
    Cescon, David W.
    Allan, Alison L.
    Parsyan, Armen
    RADIATION ONCOLOGY, 2024, 19 (01)
  • [37] PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer
    Sierra Pellizzari
    Vasudeva Bhat
    Harjot Athwal
    David W. Cescon
    Alison L. Allan
    Armen Parsyan
    Radiation Oncology, 19
  • [38] Fatty acid synthase inhibition as a potential therapeutic target in triple-negative breast cancer
    Giro, A.
    Blancafort, A.
    Oliveras, G.
    Perez-Bueno, F.
    Dorca, J.
    Vinas, G.
    Puig, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S180 - S180
  • [40] C-src: A potential target for the treatment of triple-negative breast cancer.
    Walsh, S.
    Tryfonopoulos, D.
    Quinn, C.
    Flanagan, L.
    Pierce, A.
    McDermott, E.
    Evoy, D.
    O'Donovan, N.
    Crown, J.
    Duffy, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)